BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Neuroendocrine tumors clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for neuroendocrine tumors: 339 (209 sponsors; 29 newly posted in the last 180 days, 17 stopped in the last 180 days; 12 new-entrant sponsors). Momentum score 8.8, rank 79 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 2, Phase 1 97, Phase 2 141, Phase 3 52, Phase 4 5, N/A 42.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Bristol-Myers Squibb BMY | 9 | P2 3, NA 2, P3 3, P4 1 | 0 | 1 |
| Merck Sharp & Dohme LLC MRK | 9 | P2 6, P3 3 | 0 | 1 |
| Regeneron Pharmaceuticals REGN | 7 | P3 3, P2 4 | 1 | 2 |
| IDEAYA Biosciences IDYA | 6 | P2 3, P3 3 | 1 | 3 |
| Biocad | 3 | P3 3 | 0 | 1 |
| Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 8 | P2 6, P3 2 | 1 | 2 |
| Exelixis EXEL | 4 | P3 2, P4 1, P1 1 | 2 | 0 |
| ITM Solucin GmbH | 3 | P3 2, P1 1 | 0 | 0 |
| Philogen S.p.A. | 3 | P2 1, P3 2 | 0 | 0 |
| Boehringer Ingelheim | 9 | P2 2, P1 6, P3 1 | 1 | 1 |
| Novartis Pharmaceuticals NVS | 9 | P2 2, NA 2, P1 3, P3 1, P4 1 | 1 | 1 |
| Replimune, Inc. REPL | 5 | P2 2, NA 1, P1 1, P3 1 | 0 | 0 |
| Aura Biosciences AURA | 4 | P3 1, NA 3 | 0 | 0 |
| Iovance Biotherapeutics, Inc. IOVA | 4 | P2 3, P3 1 | 0 | 0 |
| Pfizer PFE | 4 | P3 1, P1 3 | 0 | 0 |
| Advanced Accelerator Applications | 3 | P2 1, P3 1, NA 1 | 0 | 0 |
| Immatics US, Inc. IMTX | 3 | P2 1, P1 1, P3 1 | 0 | 0 |
| Amgen AMGN | 2 | P3 1, P2 1 | 0 | 0 |
| Binhui Biopharmaceutical Co., Ltd. | 2 | P2 1, P3 1 | 0 | 0 |
| Crinetics Pharmaceuticals Inc. | 2 | P2 1, P3 1 | 0 | 0 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2 | P3 1, P2 1 | 0 | 0 |
| Erasca, Inc. ERAS | 2 | P3 1, P1 1 | 0 | 0 |
| IO Biotech | 2 | P3 1, P2 1 | 0 | 0 |
| Linnaeus Therapeutics, Inc. | 2 | P3 1, P2 1 | 0 | 0 |
| Pierre Fabre Medicament | 2 | P3 1, P1 1 | 0 | 1 |
Recently stopped trials
- NCT06379217 Novartis Pharmaceuticals - terminated: Sponsor decision and not a consequence of any safety concerns. NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastati
- NCT05879822 Incyte Corporation - terminated: This was a strategic business decision. There were no safety concerns contributing to this decision. A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
- NCT06566092 Iovance Biotherapeutics, Inc. - terminated: After reviewing the available safety and efficacy data to date, Iovance has made the decision to conclude all remaining participant visits. Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
- NCT03881488 Compass Therapeutics - terminated: The combination therapy arm of the study with pembrolizumab did not yield an efficacy signal, so enrollment into the combination therapy arm Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metasta
- NCT06984328 Genmab - terminated: Genmab has decided to discontinue further clinical development of acasunlimab following strategic portfolio prioritization. The decision was Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin
- NCT05665595 Merck Sharp & Dohme LLC - terminated: Business Reason A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Partic
- NCT01029873 Altor BioScience - terminated: Sponsor decision QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
- NCT07076550 Alpha-9 Oncology USA Inc. - terminated: Due to a strategic decision to re-prioritize the sponsor's existing portfolio. A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Mela
- NCT06171178 Astellas Pharma Global Development, Inc. - terminated: Due to strategic decision made by the sponsor the study was terminated A Study of ASP1012 in Adults With Solid Tumors
- NCT05130866 Recursion Pharmaceuticals Inc. - terminated: Study was terminated due to sponsor decision. This decision was not related to safety concerns with REC-2282. Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
- NCT03114319 Novartis Pharmaceuticals - terminated: Business reasons and not due to any safety concerns Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
- NCT05571839 Seagen, a wholly owned subsidiary of Pfizer - terminated: The trial was terminated for strategic reasons. The decision was not based on any safety concerns. A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
- NCT05130255 Y-mAbs Therapeutics - terminated: Decision by Sponsor GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
- NCT04695977 Regeneron Pharmaceuticals - terminated: Business Decision CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
- NCT04916002 Regeneron Pharmaceuticals - terminated: Sponsor Decision related to study drug supply A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P3 | RayzeBio, Inc. | NCT05477576 Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | GEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Di | active not recruiting | 343 |
| 2026-12 est. | P1/P2 | Monte Rosa Therapeutics, Inc GLUE | NCT05546268 Study of Oral MRT-2359 in Selected Cancer Patients | NSCLC; SCLC; High Grade Neuroendocrine Cancer; DLBCL; L-MYC and N-MYC Amplified Solid Tumors; NSCLC | active not recruiting | 174 |
| 2026-12 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT05884255 An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. | Advanced Gastroenteropancreatic Neuroendocrine Tumor | recruiting | 220 |
| 2026-12-28 est. | P1/P2 | Nanjing Leads Biolabs Co.,Ltd | NCT06157827 A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma | Advanced Neuroendocrine Carcinoma | recruiting | 178 |
| 2026-12-31 est. | P1/P2 | Chimeric Therapeutics | NCT06055439 A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy | Neuroendocrine Tumors; Colorectal Cancer; Gastric Cancer | active not recruiting | 135 |
| 2027-01-01 est. | P2 | Biotheus Inc. | NCT05879055 A Study of PM8002 in Combination With Chemotherapy in Patients With NEN | Neuroendocrine Neoplasm | active not recruiting | 31 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P3 | Camurus AB | NCT05050942 A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET | Gastro-enteropancreatic Neuroendocrine Tumor | active not recruiting | 332 |
| 2026-10-29 | P2 | Hoffmann-La Roche | NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusio | Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, | completed | 534 |
| 2026-09 est. | P1/P2 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT05978284 Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma | Small Cell Lung Cancer; Neuroendocrine Carcinoma | recruiting | 54 |
| 2026-07 est. | P1/P2 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT06372626 Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. | Neuroendocrine Carcinoma | unknown | 93 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "neuroendocrine tumors"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.